vs
EXACT SCIENCES CORP（EXAS）与Fortive（FTV）财务数据对比。点击上方公司名可切换其他公司
Fortive的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.1B vs $878.4M），Fortive净利率更高（12.8% vs -9.8%，领先22.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs 7.7%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -17.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Fortive是总部位于美国华盛顿州埃弗里特的工业科技集团，专注于提供互联工作流解决方案所需的核心技术，研发、生产及销售专业工程类产品、软件与服务，旗下业务分为智能运营解决方案、精密技术、先进医疗解决方案三大战略板块。
EXAS vs FTV — 直观对比
营收规模更大
FTV
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出15.4%
7.7%
净利率更高
FTV
高出22.5%
-9.8%
两年增速更快
EXAS
近两年复合增速
-17.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.1B |
| 净利润 | $-86.0M | $136.4M |
| 毛利率 | 70.1% | 63.2% |
| 营业利润率 | -9.4% | 17.9% |
| 净利率 | -9.8% | 12.8% |
| 营收同比 | 23.1% | 7.7% |
| 净利润同比 | 90.1% | 21.1% |
| 每股收益（稀释后） | $-0.45 | $0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFTV
| Q1 26 | — | $1.1B | ||
| Q4 25 | $878.4M | $1.1B | ||
| Q3 25 | $850.7M | $1.0B | ||
| Q2 25 | $811.1M | $1.5B | ||
| Q1 25 | $706.8M | $1.5B | ||
| Q4 24 | $713.4M | $1.6B | ||
| Q3 24 | $708.7M | $1.5B | ||
| Q2 24 | $699.3M | $1.6B |
净利润EXASFTV
| Q1 26 | — | $136.4M | ||
| Q4 25 | $-86.0M | $185.7M | ||
| Q3 25 | $-19.6M | $55.0M | ||
| Q2 25 | $-1.2M | $166.6M | ||
| Q1 25 | $-101.2M | $171.9M | ||
| Q4 24 | $-864.6M | $208.8M | ||
| Q3 24 | $-38.2M | $221.6M | ||
| Q2 24 | $-15.8M | $195.1M |
毛利率EXASFTV
| Q1 26 | — | 63.2% | ||
| Q4 25 | 70.1% | 63.2% | ||
| Q3 25 | 68.6% | 63.2% | ||
| Q2 25 | 69.3% | 59.0% | ||
| Q1 25 | 70.8% | 59.8% | ||
| Q4 24 | 69.0% | 60.3% | ||
| Q3 24 | 69.4% | 60.0% | ||
| Q2 24 | 69.8% | 59.8% |
营业利润率EXASFTV
| Q1 26 | — | 17.9% | ||
| Q4 25 | -9.4% | 20.1% | ||
| Q3 25 | -3.0% | 15.5% | ||
| Q2 25 | -0.3% | 14.6% | ||
| Q1 25 | -13.6% | 15.8% | ||
| Q4 24 | -122.8% | 19.0% | ||
| Q3 24 | -5.6% | 19.3% | ||
| Q2 24 | -3.8% | 19.4% |
净利率EXASFTV
| Q1 26 | — | 12.8% | ||
| Q4 25 | -9.8% | 16.5% | ||
| Q3 25 | -2.3% | 5.4% | ||
| Q2 25 | -0.1% | 11.0% | ||
| Q1 25 | -14.3% | 11.7% | ||
| Q4 24 | -121.2% | 12.9% | ||
| Q3 24 | -5.4% | 14.4% | ||
| Q2 24 | -2.3% | 12.6% |
每股收益（稀释后）EXASFTV
| Q1 26 | — | $0.44 | ||
| Q4 25 | $-0.45 | $0.60 | ||
| Q3 25 | $-0.10 | $0.16 | ||
| Q2 25 | $-0.01 | $0.49 | ||
| Q1 25 | $-0.54 | $0.50 | ||
| Q4 24 | $-4.69 | $0.60 | ||
| Q3 24 | $-0.21 | $0.63 | ||
| Q2 24 | $-0.09 | $0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $356.1M |
| 总债务越低越好 | — | $3.5B |
| 股东权益账面价值 | $2.4B | $6.1B |
| 总资产 | $5.9B | $11.6B |
| 负债/权益比越低杠杆越低 | — | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资EXASFTV
| Q1 26 | — | $356.1M | ||
| Q4 25 | $964.7M | $375.5M | ||
| Q3 25 | $1.0B | $430.8M | ||
| Q2 25 | $858.4M | $1.8B | ||
| Q1 25 | $786.2M | $892.1M | ||
| Q4 24 | $1.0B | $813.3M | ||
| Q3 24 | $1.0B | $811.3M | ||
| Q2 24 | $946.8M | $644.1M |
总债务EXASFTV
| Q1 26 | — | $3.5B | ||
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.3B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $3.9B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.9B | ||
| Q2 24 | — | $3.8B |
股东权益EXASFTV
| Q1 26 | — | $6.1B | ||
| Q4 25 | $2.4B | $6.5B | ||
| Q3 25 | $2.5B | $6.5B | ||
| Q2 25 | $2.5B | $10.4B | ||
| Q1 25 | $2.4B | $10.2B | ||
| Q4 24 | $2.4B | $10.2B | ||
| Q3 24 | $3.2B | $10.6B | ||
| Q2 24 | $3.2B | $10.5B |
总资产EXASFTV
| Q1 26 | — | $11.6B | ||
| Q4 25 | $5.9B | $11.7B | ||
| Q3 25 | $5.9B | $11.9B | ||
| Q2 25 | $5.8B | $18.2B | ||
| Q1 25 | $5.7B | $17.1B | ||
| Q4 24 | $5.9B | $17.0B | ||
| Q3 24 | $6.7B | $17.5B | ||
| Q2 24 | $6.7B | $17.3B |
负债/权益比EXASFTV
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $234.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFTV
| Q1 26 | — | $234.8M | ||
| Q4 25 | $151.7M | $1.1B | ||
| Q3 25 | $219.9M | $164.4M | ||
| Q2 25 | $89.0M | $311.2M | ||
| Q1 25 | $30.8M | $241.7M | ||
| Q4 24 | $47.1M | $502.2M | ||
| Q3 24 | $138.7M | $459.0M | ||
| Q2 24 | $107.1M | $308.9M |
自由现金流EXASFTV
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $313.8M | ||
| Q3 25 | $190.0M | $153.1M | ||
| Q2 25 | $46.7M | $274.5M | ||
| Q1 25 | $-365.0K | $215.0M | ||
| Q4 24 | $10.7M | $465.2M | ||
| Q3 24 | $112.6M | $431.2M | ||
| Q2 24 | $71.2M | $279.7M |
自由现金流率EXASFTV
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 28.0% | ||
| Q3 25 | 22.3% | 14.9% | ||
| Q2 25 | 5.8% | 18.1% | ||
| Q1 25 | -0.1% | 14.6% | ||
| Q4 24 | 1.5% | 28.7% | ||
| Q3 24 | 15.9% | 28.1% | ||
| Q2 24 | 10.2% | 18.0% |
资本支出强度EXASFTV
| Q1 26 | — | 2.5% | ||
| Q4 25 | 3.6% | 2.7% | ||
| Q3 25 | 3.5% | 1.1% | ||
| Q2 25 | 5.2% | 2.4% | ||
| Q1 25 | 4.4% | 1.8% | ||
| Q4 24 | 5.1% | 2.3% | ||
| Q3 24 | 3.7% | 1.8% | ||
| Q2 24 | 5.1% | 1.9% |
现金转化率EXASFTV
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | 5.83× | ||
| Q3 25 | — | 2.99× | ||
| Q2 25 | — | 1.87× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | — | 2.41× | ||
| Q3 24 | — | 2.07× | ||
| Q2 24 | — | 1.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FTV
暂无分部数据
